GSK PLC (LSE:GSK, NYSE:GSK) got a grudging nod from Citi on Thursday, as the investment bank lifted its earnings forecasts for the drugmaker but stopped well short of a buy call. The shares edged up 0.31% to 1,922p as Citi kept its 'neutral' rating, tweaking its model after GSK's...

Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.

On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to £2.80 billion and Core EPS rose 9% CER […]

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.

(Bloomberg) -- President Donald Trump is expected to sign an executive order Monday that would recommend breaking up the combined measles, mumps and rubella vaccine into three separate shots, according to a person familiar with the matter. Most Read from BloombergChina Unleashes $28 Trillion Capital Markets to Challenge US in AIStocks Wobble on Hormuz Standoff as Nvidia Sinks: Markets WrapIran Shakes Up Security Team After Saying Oman Deal ‘Very Close’Trump Amps Up Pressure on Billionaire Sargea

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

GSK (LSE:GSK) plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK. The site is expected to accommodate more than 1,000 scientists and support closer work with nearby research institutions and biotechs. GSK has also agreed a research collaboration with Relation Therapeutics that uses advanced cellular biology models and large-scale data generation. GSK is a large global biopharma company, and this move into the Cambridge Biomedical Campus places it at the...

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

GSK PLC (GSK) reports Q2 sales up 5% to over GBP8.4 billion and launches a GBP1.9 billion cost-saving program, but lowers 2026 EPS guidance due to Nuvalent acquisition costs.

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

GILD heads into Q2 earnings with HIV franchise strength, rising Yeztugo expectations and oncology progress, even as Cell Therapy faces competitive pressure.

GSK plans to reinvest savings into more than 20 late-stage study starts as patent expirations approach.

GSK (NYSE:GSK) reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and investment program intended to accelerate its late-stage pipeline and support growth beyond 2031. Luk

GlaxoSmithKline (GSK) will invest £400m in a major new science hub in Cambridge as part of plans to pour more money into developing new cancer drugs.

GlaxoSmithKline (GSK) will invest £400m in a major new science hub in Cambridge as part of plans to pour more money into developing new cancer drugs.

Glaxo (GSK) delivered earnings and revenue surprises of +7.09% and +4.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company’s 2031 sales target.

The move will impact around 1,800 staff currently based in Stevenage.

GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and accelerated investment in its pipeline. Revenue rose 5% to £8.41 billion, ahead of the £8.25 billion City consensus. Adjusted earnings per share...

Intel's AI infrastructure push, Dell's AI server boom and Progressive's premium growth highlight the latest top research reports and key opportunities.

GSK stock has delivered a 65.0% return over the past five years, yet its valuation checks still lean supportive, raising the question of whether the recent oncology news flow is fully reflected in the current share price. Over the past 5 years, GSK has returned 65.0%, which puts recent short term price softness into the context of a solid longer term gain. Regulatory progress for oncology drugs such as Jideytro and Jemperli can support higher earnings expectations, while setbacks like the...

GSK (LSE:GSK) has just received US FDA approval for Jideytro, a ROS1 selective inhibitor for previously treated ROS1 positive non small cell lung cancer. This gives the stock a fresh catalyst from its oncology pipeline. See our latest analysis for GSK. Despite the Jideytro approval, GSK’s share price has eased in recent weeks, with a 30 day share price return of 2.66% down and a 90 day return of 5.67% down, while the 1 year total shareholder return of 42.21% and 5 year total shareholder...

GSK (LSE:GSK) received US FDA approval for Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, its first approved lung cancer medicine. The company submitted an application to the EMA to update the label for Bexsero, aiming to expand information on use in adolescents and young adults for invasive meningococcal disease prevention. Positive phase II results for Jemperli in locally advanced rectal cancer indicate potential for an immunotherapy option that...

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.